These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 9494734)

  • 1. PCR-based method for the introduction of mutations in genes cloned and expressed in vaccinia virus.
    Lorenzo MM; Blasco R
    Biotechniques; 1998 Feb; 24(2):308-13. PubMed ID: 9494734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel vaccinia virus expression system allowing construction of recombinants without the need for selection markers, plasmids and bacterial hosts.
    Pfleiderer M; Falkner FG; Dorner F
    J Gen Virol; 1995 Dec; 76 ( Pt 12)():2957-62. PubMed ID: 8847500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An efficient method for generating poxvirus recombinants in the absence of selection.
    Rice AD; Gray SA; Li Y; Damon I; Moyer RW
    Viruses; 2011 Mar; 3(3):217-32. PubMed ID: 21494427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Construction and evaluation of a new triple-gene expression cassette vaccinia virus shuttle vector.
    Du S; Li C; Wang Y; Liu C; Ren D; Li Y; Qin Y; Wang M; Sun D; Zhu N; Jin N
    J Virol Methods; 2012 Nov; 185(2):175-83. PubMed ID: 22766182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A PCR-based method for manipulation of the vaccinia virus genome that eliminates the need for cloning.
    Turner PC; Moyer RW
    Biotechniques; 1992 Nov; 13(5):764-71. PubMed ID: 1418979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BiZyme: a novel fusion protein-mediating selection of vaccinia virus recombinants by fluorescence and antibiotic resistance.
    Hansen SG; Cope TA; Hruby DE
    Biotechniques; 2002 May; 32(5):1178, 1180, 1182-7. PubMed ID: 12019792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Green fluorescent protein expressed by a recombinant vaccinia virus permits early detection of infected cells by flow cytometry.
    Domínguez J; Lorenzo MM; Blasco R
    J Immunol Methods; 1998 Nov; 220(1-2):115-21. PubMed ID: 9839932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The combination of marker gene swapping and fluorescence-activated cell sorting improves the efficiency of recombinant modified vaccinia virus Ankara vaccine production for human use.
    Di Lullo G; Soprana E; Panigada M; Palini A; Agresti A; Comunian C; Milani A; Capua I; Erfle V; Siccardi AG
    J Virol Methods; 2010 Feb; 163(2):195-204. PubMed ID: 19778556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transient selection during vaccinia virus recombination with insertion vectors without selectable markers.
    Kurilla MG
    Biotechniques; 1997 May; 22(5):906-10. PubMed ID: 9149873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MAVERICC: Marker-free Vaccinia Virus Engineering of Recombinants through in vitro CRISPR/Cas9 Cleavage.
    Laudermilch E; Chandran K
    J Mol Biol; 2021 Apr; 433(9):166896. PubMed ID: 33639215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Construction and isolation of recombinant vaccinia virus using genetic markers.
    Lorenzo MM; Galindo I; Blasco R
    Methods Mol Biol; 2004; 269():15-30. PubMed ID: 15114004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Puromycin resistance (pac) gene as a selectable marker in vaccinia virus.
    Sánchez-Puig JM; Blasco R
    Gene; 2000 Oct; 257(1):57-65. PubMed ID: 11054568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Construction and identification of the replication-deficient recombinant vaccinia virus co-expressing HPV type 16 L1 and L2 proteins].
    Han L; Ren J; Liang Y; Tian H; Zhi H; Luo W; Lu Z; Wei L; Ruan L
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2002 Sep; 16(3):256-60. PubMed ID: 12665934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isolation of vaccinia MVA recombinants using the viral F13L gene as the selective marker.
    Sánchez-Puig JM; Blasco R
    Biotechniques; 2005 Nov; 39(5):665-6, 668, 670 passim. PubMed ID: 16312215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transient host range selection for genetic engineering of modified vaccinia virus Ankara.
    Staib C; Drexler I; Ohlmann M; Wintersperger S; Erfle V; Sutter G
    Biotechniques; 2000 Jun; 28(6):1137-42, 1144-6, 1148. PubMed ID: 10868279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transient and inducible expression of vaccinia/T7 recombinant viruses.
    Mohamed MR; Niles EG
    Methods Mol Biol; 2004; 269():41-50. PubMed ID: 15114006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Construction of recombinant vaccinia viruses using leporipoxvirus-catalyzed recombination and reactivation of orthopoxvirus DNA.
    Yao XD; Evans DH
    Methods Mol Biol; 2004; 269():51-64. PubMed ID: 15114007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasmodium knowlesi sporozoite antigen: expression by infectious recombinant vaccinia virus.
    Smith GL; Godson GN; Nussenzweig V; Nussenzweig RS; Barnwell J; Moss B
    Science; 1984 Apr; 224(4647):397-9. PubMed ID: 6200932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Marker gene swapping facilitates recombinant Modified Vaccinia Virus Ankara production by host-range selection.
    Di Lullo G; Soprana E; Panigada M; Palini A; Erfle V; Staib C; Sutter G; Siccardi AG
    J Virol Methods; 2009 Mar; 156(1-2):37-43. PubMed ID: 19038289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of recombinant vaccinia viruses via green fluorescent protein selection.
    Popov S; Mirshahidi S; Essono S; Song R; Wang X; Ruprecht RM
    DNA Cell Biol; 2009 Mar; 28(3):103-8. PubMed ID: 19182996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.